These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1359785)

  • 1. The many faces of scleroderma.
    Smiley JD
    Am J Med Sci; 1992 Nov; 304(5):319-33. PubMed ID: 1359785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical approach to scleroderma.
    White B
    Semin Cutan Med Surg; 1998 Sep; 17(3):213-8. PubMed ID: 9759679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.
    Clements PJ
    Curr Opin Rheumatol; 1994 Nov; 6(6):603-6. PubMed ID: 7865380
    [No Abstract]   [Full Text] [Related]  

  • 5. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Raynaud's phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory.
    Czirják L; Matucci-Cerinic M
    Rheumatology (Oxford); 2011 Feb; 50(2):250-1. PubMed ID: 21115465
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy.
    Ingegnoli F; Boracchi P; Gualtierotti R; Biganzoli EM; Zeni S; Lubatti C; Fantini F
    Rheumatology (Oxford); 2010 Apr; 49(4):797-805. PubMed ID: 20100796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma mimics - Clinical features and management.
    Orteu CH; Ong VH; Denton CP
    Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101489. PubMed ID: 32147386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Sclerosis with Focus on Scleroderma Renal Crisis.
    Pasha F; Abazari S; Bikarannejad P; Zabolian A
    Iran J Kidney Dis; 2019 May; 13(3):207-210. PubMed ID: 31209194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis.
    Shuck JW; Oetgen WJ; Tesar JT
    Am J Med; 1985 Feb; 78(2):221-7. PubMed ID: 3970048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scleroderma and related disorders: therapeutic aspects.
    Denton CP; Black CM
    Baillieres Best Pract Res Clin Rheumatol; 2000 Mar; 14(1):17-35. PubMed ID: 10882212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.
    Shanmugam VK; Frech TM; Steen VD; Hummers LK; Shah AA; Bernstein EJ; Khanna D; Gordon JK; Castelino FV; Chung L; Hant FN; Startup E; VanBuren JM; Evnin LB; Assassi S
    Clin Rheumatol; 2020 Jan; 39(1):93-102. PubMed ID: 31667644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis.
    Galluccio F; Matucci-Cerinic M
    Autoimmun Rev; 2011 Mar; 10(5):241-3. PubMed ID: 20863907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
    Ferreli C; Gasparini G; Parodi A; Cozzani E; Rongioletti F; Atzori L
    Clin Rev Allergy Immunol; 2017 Dec; 53(3):306-336. PubMed ID: 28712039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cold and emotional stress in Raynaud's disease and scleroderma.
    Freedman RR; Ianni P
    Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the diagnosis and management of scleroderma-related vascular complications.
    Kerin K; Yost JH
    Compr Ther; 1998; 24(11-12):574-81. PubMed ID: 9847974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon.
    Seibold JR; Harris JN
    J Rheumatol; 1985 Feb; 12(1):99-103. PubMed ID: 2580093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.